Relay Therapeutics Files 8-K

Ticker: RLAY · Form: 8-K · Filed: Sep 9, 2024 · CIK: 1812364

Relay Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyRelay Therapeutics, Inc. (RLAY)
Form Type8-K
Filed DateSep 9, 2024
Risk Levellow
Pages6
Reading Time7 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, 8-k, disclosure

Related Tickers: RLAY

TL;DR

Relay Therapeutics filed an 8-K. Check for updates.

AI Summary

On September 9, 2024, Relay Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and other events, along with financial statements and exhibits. No specific financial figures or new material events were detailed in the provided excerpt.

Why It Matters

This filing indicates Relay Therapeutics is providing updates or disclosures to the SEC, which could contain material information for investors.

Risk Assessment

Risk Level: low — The provided excerpt is a standard SEC filing notification without specific material events or financial data, making the immediate risk assessment low.

Key Players & Entities

  • Relay Therapeutics, Inc. (company) — Registrant
  • 0000950170-24-104557 (filing_id) — Accession Number
  • September 09, 2024 (date) — Date of earliest event reported
  • 399 Binney Street (address) — Principal Executive Offices
  • Cambridge (location) — City
  • Massachusetts (location) — State
  • 02142 (zip_code) — Principal Executive Offices
  • (617) 370-8837 (phone_number) — Registrant's Telephone Number

FAQ

What specific event triggered this 8-K filing?

The filing indicates it is for Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits, but the specific triggering event is not detailed in the provided excerpt.

When was the earliest event reported in this filing?

The earliest event reported is dated September 09, 2024.

What is Relay Therapeutics, Inc.'s principal executive office address?

The principal executive office is located at 399 Binney Street, Cambridge, Massachusetts 02142.

What is the Commission File Number for Relay Therapeutics, Inc.?

The Commission File Number is 001-39385.

What is the IRS Employer Identification Number for Relay Therapeutics, Inc.?

The IRS Employer Identification Number is 47-3923475.

Filing Stats: 1,816 words · 7 min read · ~6 pages · Grade level 15.5 · Accepted 2024-09-09 08:00:16

Key Financial Figures

  • $0.001 — ch registered Common Stock, par value $0.001 per share RLAY Nasdaq Global Market

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On September 9, 2024, Relay Therapeutics, Inc. (the "Company") issued a press release announcing interim clinical data for RLY-2608, the first known allosteric, pan-mutant and isoform-selective inhibitor of phosphoinostide 3 kinase alpha ("PI3K"), a copy of which is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K. The Company intends to host a conference call and live webcast to discuss the interim clinical data on September 9, 2024 at 8:00 a.m. E.T. The Company has made available a slide presentation to accompany the call, a copy of which is being furnished as Exhibit 99.2 to this Current Report on Form 8-K. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.2. The information in this Item 7.01, including Exhibit 99.1 and Exhibit 99.2 attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

01 Other Events

Item 8.01 Other Events. RLY-2608 On September 9, 2024, the Company announced interim clinical data for RLY-2608. RLY-2608 is currently being evaluated in the Company's ReDiscover Trial, an ongoing first-in-human study, which was designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary antitumor activity of RLY-2608 alone, in combination with fulvestrant, and in combination with fulvestrant and ribociclib or atirmociclib. The interim clinical data were based on an August 12, 2024 interim data cut-off date. As of such date, the RLY-2608 and fulvestrant combination arm of the study had enrolled 118 patients with PI3K-mutated, HR+, HER2– locally advanced or metastatic breast cancer across all doses in both the dose escalation and dose expansion portions of the study, including 64 patients at the Company's recommended Phase 2 dose ("RP2D") of 600mg twice daily (17 in dose escalation and 47 in dose expansion). Among these 64 patients, 31 had a kinase mutation and 33 had a non-kinase mutation. Twelve patients also had a PTEN or AKT co-mutation and were therefore excluded from the efficacy analysis, consistent with the currently proposed pivotal population. All patients across doses had received a significant level of prior therapy in the advanced setting, including at least one prior endocrine therapy and at least one prior CDK4/6 inhibitor. Among the 64 patients who received the RP2D: 45% of patients (n=29) had received two or more prior lines of therapy; 52% of patients (n=33) had received a prior selective estrogen-receptor degrader ("SERD"), such as fulvestrant or a novel SERD; 25% of patients (n=16) had received chemotherapy or an ADC; 59% percent of patients (n=38) had visceral metastases; and 34% of patients (n=22) had a BMI of at least 30 and/or HbA1c of at least 5.7%. Among the 52 patients who received the RP2D and did not have a PTEN or AKT co-mutation: Median progression free survival was 9.2 months

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. 99.1 Press release issued by Relay Therapeutics, Inc. on September 9, 2024, furnished herewith. 99.2 Corporate presentation, dated September 9, 2024, furnished herewith . 104 Cover Page Interactive Data File (embedded within Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. RELAY THERAPEUTICS, INC. Date: September 9, 2024 By: /s/ Brian Adams Brian Adams Chief Legal Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.